AbbVie Inc.
ABBV
NYSE
Last Updated: 6/9/2023 8:03:10 PM
High
Low
About AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.AbbVie Inc. Company Details
CEO: Mr. Richard A. Gonzalez
Country: US
Industry: Drug Manufacturers—General
Website: https://www.abbvie.com
Exchange: New York Stock Exchange
IPO\Launch Date: 2013-01-02
AbbVie Inc. Company Executive Details
Ms. Elizabeth Shea
Vice President of Investor Relations
Ms. Rae L. Livingston
Chief Equity Officer
Mr. Jeffrey Ryan Stewart
Executive Vice President & Chief Commercial Officer
Mr. Robert A. Michael
Vice Chairman & Pres
Dr. Azita Saleki-Gerhardt Ph.D.
Executive Vice President of Operations
AbbVie Inc. Latest News
4 Factor Dividend Growth Portfolio - Passively Outpacing The Market
The 4-factor dividend growth portfolio is a strategy that leverages the stock selection process of Schwab U.S. Dividend Equity ETF™, with a few minor twists. The portfolio gained 1.84% in May, outperforming the S&P 500 by 1.40%. Year-to-date the portfolio is up 6.66% and trailing the S&P 500 by 2.99%. Since inception, the portfolio is generating alpha over the S&P 500.
Published on: 2023-06-09 17:39:31
Impact on Symbol / Company: ABBV
View News
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Published on: 2023-06-09 10:12:07
Impact on Symbol / Company: ABBV
View News
NY AG approves $17.3 billion opioid settlement with CVS, Walgreens, Teva and AbbVie's Allergan
New York Attorney General Letitia James announced Friday the final approval of $17.3 billion in national settlement agreements with drug-store chains CVS Health Corp. CVS, and Walgreens Boots Alliance Inc. WBA, -0.68%, and with drug makers Teva Pharmaceutical Industries Ltd. TEVA, -0.61% and AbbVie Inc.'s ABBV, +0.61% Allergan.
Published on: 2023-06-09 10:09:00
Impact on Symbol / Company: ABBV
View News
4 Dividend Aristocrat Buys For June And 5 To Watch
"Dividend Aristocrats in the S&P 500 Index have raised their annual payouts every year for at least 25 consecutive years. "--Kiplinger.com/Investing. 67 Aristocrats, screened as of June 6, 2023, represented all eleven Morningstar Sectors. Broker estimated-top-ten net-gains ranged 20.58%-43.58% topped-by TGT & VFC. By yield, VFC topped-all Aristocrats. Top-ten Yields from TROW, ABBV, FRT, BEN, AMCR, IBM, O, WBA, MMM, & VFC, averaged 5.15%.
Published on: 2023-06-08 18:59:40
Impact on Symbol / Company: ABBV
View News
Is AbbVie or Amgen the Better Bargain Buy Right Now?
Exclusivity losses can be big setbacks for pharma companies. AbbVie and Amgen both face this key overhang.
Published on: 2023-06-08 12:15:00
Impact on Symbol / Company: ABBV
View News
$300 a Month in These 3 Stocks Could Make You a Millionaire by Retirement
AbbVie's drug portfolio and pipeline are both exceptional. Air Products & Chemicals is a wonderful business in a pivotal industry.
Published on: 2023-06-06 07:30:00
Impact on Symbol / Company: ABBV
View News
10 Dividend Aristocrats For The Ultimate 6% Yielding Retirement Portfolio
The NY Fed estimates a 68% recession probability within the next 12 months, the highest risk in 42 years. Dividend aristocrats can provide a relatively safe investment option during a recession, with a history of raising dividends through economic downturns and much lower volatility. A diversified high-yield portfolio of dividend aristocrats can offer market-like returns with lower volatility and higher yield.
Published on: 2023-06-03 07:45:00
Impact on Symbol / Company: ABBV
View News
7 Best Dividend Stocks to Buy Now in June 2023
These top dividend stocks are attractive at these levels and lower, and they add excellent diversity to a long-term investing portfolio.
Published on: 2023-06-01 16:23:28
Impact on Symbol / Company: ABBV
View News
Why AbbVie and Amgen Are Moving Lower Today
Today, Coherus and Mark Cuban announced a partnership to launch an ultra-low-priced Humira biosimilar. This steep discount might have negative consequences for both AbbVie and Amgen later on this year.
Published on: 2023-06-01 12:50:20
Impact on Symbol / Company: ABBV
View News
Buy 7 June Dividend Kings And Watch 3
"There is only one-criterion to be included among the Dividend Kings: a publicly-traded company must increase its total fiscal-year dividend-payout for a minimum of 50 consecutive-years."--Dogs of the Dow. The 47 Dividend Kings screened as of May 26, 2023, represented eight of eleven Morningstar Sectors. Broker targeted-top-ten net-gainers ranged 16.08%-39.93% topped-by VF Corp & Gorman-Rupp. By yield, MO tops-all. Top-ten Kingly June yields from BKH, ABBV, NWN, FRT, CDUAF, LEG, UVV, MMM, VFC, & MO averaged 5.59%.
Published on: 2023-05-31 16:34:47
Impact on Symbol / Company: ABBV
View News
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Published on: 2023-05-29 10:05:14
Impact on Symbol / Company: ABBV
View News
Buy Alert: 3 Undervalued High-Yield Gems For Your Retirement
This article discusses three high-yielding stocks for retirees and income-oriented investors: ONEOK, AbbVie, and Realty Income. ONEOK is a cyclical income play with a 6.5% yield, AbbVie offers a high-quality healthcare yield of 4.2%, and Realty Income provides steady and reliable dividend growth with a 5.2% yield.
Published on: 2023-05-26 09:00:00
Impact on Symbol / Company: ABBV
View News
Grow your Money
We helps you in understanding the science behind growing the money, which will help you diversify your funds as per your requirements and helps in achieving your retirement goals, children education, investment in property, business or any smart looking startup ventures
Services we Offer
We offer several services including expert recommendations & suggestions on buying ETF, Mutual Funds, Bonds, Debt securities, Equities, Property invesments and several others
Live Market Data
We provide you live market data for your analysis, review and looking out for quick buying opportunities to help you